shutterstock_1871127568_rafapress

rafapress / Shutterstock.com

7 November 2023Big PharmaMarisa Woutersen

Court partially grants disqualification of PacBio’s legal team

Genomics company’s in-house attorney removed from case over links with patent infringement case | Court denied plaintiff’s motion to disqualify entire legal team.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Oxford Nanopore secures Fed Circ victory in PacBio DNA suit

13 May 2021 The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.

Personal Genomics takes PacBio dispute to Chinese court

22 May 2020 Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.

More on this story

Oxford Nanopore secures Fed Circ victory in PacBio DNA suit

13 May 2021 The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.

Personal Genomics takes PacBio dispute to Chinese court

22 May 2020 Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.

More on this story

Oxford Nanopore secures Fed Circ victory in PacBio DNA suit

13 May 2021 The US Court of Appeals for the Federal Circuit has upheld a district court jury decision that found Pacific Biosciences’ DNA sequencing patents—which it had asserted against Oxford Nanopore Technologies—were invalid.

Personal Genomics takes PacBio dispute to Chinese court

22 May 2020 Taiwanese biotechnology company Personal Genomics is using California’s Pacific Biosciences for patent infringement in China.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages